{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:26:28Z","timestamp":1790835988266,"version":"4.1.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Hereditary or developmental neurological disorders (HNDs or DNDs) affect the quality of life and contribute to the high mortality rates among neonates. Most HNDs are incurable, and the search for new and effective treatments is hampered by challenges peculiar to the human brain, which is guarded by the near-impervious blood-brain barrier. Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR), a gene-editing tool repurposed from bacterial defense systems against viruses, has been touted by some as a panacea for genetic diseases. CRISPR has expedited the research into HNDs, enabling the generation of <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> models to simulate the changes in human physiology caused by genetic variation. In this review, we describe the basic principles and workings of CRISPR and the modifications that have been made to broaden its applications. Then, we review important CRISPR-based studies that have opened new doors to the treatment of HNDs such as fragile X syndrome and Down syndrome. We also discuss how CRISPR can be used to generate research models to examine the effects of genetic variation and caffeine therapy on the developing brain. Several drawbacks of CRISPR may preclude its use at the clinics, particularly the vulnerability of neuronal cells to the adverse effect of gene editing, and the inefficiency of CRISPR delivery into the brain. In concluding the review, we offer some suggestions for enhancing the gene-editing efficacy of CRISPR and how it may be morphed into safe and effective therapy for HNDs and other brain disorders.<\/jats:p>","DOI":"10.3389\/fped.2021.592571","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:18:45Z","timestamp":1615439925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["CRISPR Gene-Editing Models Geared Toward Therapy for Hereditary and Developmental Neurological Disorders"],"prefix":"10.3389","volume":"9","author":[{"given":"Poh Kuan","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fook Choe","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiful Effendi","family":"Syafruddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Aiman","family":"Mohtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norazrina","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Yuen","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng Wee","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40246-019-0216-4","article-title":"Essential genetic findings in neurodevelopmental disorders","volume":"13","author":"Cardoso","year":"2019","journal-title":"Hum Genom"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9781118963418.childpsy202","article-title":"Brain and cognitive development","volume":"2","author":"Stiles","year":"2015","journal-title":"Handb Child Psychol Dev Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.gpb.2019.11.003","article-title":"Big data and the brain: peeking at the future","volume":"17","author":"Qu","year":"2019","journal-title":"Genom Proteomics Bioinform"},{"key":"B4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","article-title":"Gene therapy tools for brain diseases","volume":"10","author":"Ingusci","year":"2019","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","article-title":"Progress in gene therapy for neurological disorders","volume":"9","author":"Simonato","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2008.04.022","article-title":"Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis","volume":"213","author":"Sondhi","year":"2008","journal-title":"Exp Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1172\/JCI72992","article-title":"Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9","volume":"124","author":"Gupta","year":"2014","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41467-020-15053-x","article-title":"Multiplexed CRISPR technologies for gene editing and transcriptional regulation","volume":"11","author":"McCarty","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"eab7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours","volume":"2","author":"Lee","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1038\/s41598-017-15033-0","article-title":"Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology","volume":"7","author":"Abe","year":"2017","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/onc.2016.382","article-title":"Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer","volume":"36","author":"Harrod","year":"2017","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","first-page":"00330-2019","DOI":"10.1183\/23120541.00330-2019","article-title":"Caffeine in preterm infants: where are we in 2020?","volume":"6","author":"Moschino","year":"2020","journal-title":"ERJ Open Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1111\/j.1651-2227.2012.02664.x","article-title":"Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity","volume":"101","author":"Kumral","year":"2012","journal-title":"Acta paediatrica (Oslo, Norway: 1992)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/TACG.S8873","article-title":"Gene therapy for the treatment of cystic fibrosis","volume":"5","author":"Burney","year":"2012","journal-title":"Appl Clin Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/hum.2019.225","article-title":"Sexually divergent mortality and partial phenotypic rescue after gene therapy in a mouse model of dravet syndrome","volume":"31","author":"Niibori","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1093\/hmg\/ddv309","article-title":"Proteins linked to autosomal dominant and autosomal recessive disorders harbor characteristic rare missense mutation distribution patterns","volume":"24","author":"Turner","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/bjophthalmol-2015-308329","article-title":"Genetic manipulation for inherited neurodegenerative diseases: myth or reality?","volume":"100","author":"Yu-Wai-Man","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl Neurodegen"},{"key":"B25","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B26","first-page":"1612","article-title":"Death but one unintended consequence of gene-therapy trial","volume":"164","author":"Sibbald","year":"2001","journal-title":"CMAJ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/ncomms1937","article-title":"Molecular memory of prior infections activates the CRISPR\/Cas adaptive bacterial immunity system","volume":"3","author":"Datsenko","year":"2012","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science (New York, NY)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science (New York, NY)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.dnarep.2008.06.018","article-title":"Comparison of nonhomologous end joining and homologous recombination in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"DNA Repair"},{"key":"B32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5483\/BMBRep.2019.52.8.149","article-title":"Evolution of CRISPR towards accurate and efficient mammal genome engineering","volume":"52","author":"Ryu","year":"2019","journal-title":"BMB Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1038\/s41598-019-41121-4","article-title":"Highly efficient genome editing for single-base substitutions using optimized ssODNs with Cas9-RNPs","volume":"9","author":"Okamoto","year":"2019","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5483\/BMBRep.2018.51.9.187","article-title":"The road less traveled: strategies to enhance the frequency of homology-directed repair (HDR) for increased efficiency of CRISPR\/Cas-mediated transgenesis","volume":"51","author":"Devkota","year":"2018","journal-title":"BMB Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.ymthe.2018.08.007","article-title":"Correction of the marfan syndrome pathogenic FBN1 mutation by base editing in human cells and heterozygous embryos","volume":"26","author":"Zeng","year":"2018","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s13238-017-0459-6","article-title":"Highly efficient base editing in human tripronuclear zygotes","volume":"8","author":"Zhou","year":"2017","journal-title":"Protein Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"B40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1749-6632.2010.05819.x","article-title":"Genetic regulation of human brain development: lessons from Mendelian diseases","volume":"1214","author":"Dixon-Salazar","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13059-018-1424-2","article-title":"Redefining mouse transgenesis with CRISPR\/Cas9 genome editing technology","volume":"19","author":"Burgio","year":"2018","journal-title":"Genome Biol"},{"key":"B42","first-page":"1359","article-title":"Legal and ethical implications of crispr applications in psychiatry","volume":"97","author":"Foulkes","year":"2019","journal-title":"N C Law Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"15038","DOI":"10.1038\/ncomms15038","article-title":"Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells","volume":"8","author":"Fink","year":"2017","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/aur.2267","article-title":"Generation of a novel rat model of angelman syndrome with a complete Ube3a gene deletion","volume":"13","author":"Dodge","year":"2020","journal-title":"Autism Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/cr.2015.130","article-title":"CRISPR\/Cas9-mediated genome engineering of the ferret","volume":"25","author":"Kou","year":"2015","journal-title":"Cell Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.celrep.2017.08.024","article-title":"Folding of the cerebral cortex requires Cdk5 in upper-layer neurons in gyrencephalic mammals","volume":"20","author":"Shinmyo","year":"2017","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1038\/s41598-019-45859-9","article-title":"CRISPR\/Cas9 mediated generation of an ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease)","volume":"9","author":"Eaton","year":"2019","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrn3707","article-title":"Growth and folding of the mammalian cerebral cortex: from molecules to malformations","volume":"15","author":"Sun","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1242\/dmm.026120","article-title":"Rodent models in neuroscience research: is it a rat race?","volume":"9","author":"Ellenbroek","year":"2016","journal-title":"Dis Model Mech"},{"key":"B50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41586-019-1506-7","article-title":"Conserved cell types with divergent features in human versus mouse cortex","volume":"573","author":"Hodge","year":"2019","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13024-019-0321-9","article-title":"A CRISPR monkey model unravels a unique function of PINK1 in primate brains","volume":"14","author":"Yang","year":"2019","journal-title":"Mol Neurodegen"},{"key":"B52","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/B978-012263951-7\/50016-8","article-title":"Biology and diseases of ferrets","author":"Marini","year":"2002","journal-title":"Lab Anim Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0300985811400441","article-title":"Clinical and pathologic features of neuronal ceroid-lipofuscinosis in a ferret (Mustela putorius furo)","volume":"48","author":"Nibe","year":"2011","journal-title":"Vet Pathol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41422-019-0142-y","article-title":"CRISPR\/Cas9-mediated PINK1 deletion leads to neurodegeneration in rhesus monkeys","volume":"29","author":"Yang","year":"2019","journal-title":"Cell Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13059-017-1354-4","article-title":"CRISPR\/Cas9-mediated targeted chromosome elimination","volume":"18","author":"Zuo","year":"2017","journal-title":"Genome Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41434-019-0120-5","article-title":"A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases","volume":"27","author":"Ou","year":"2020","journal-title":"Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12910-019-0411-9","article-title":"Is selecting better than modifying? An investigation of arguments against germline gene editing as compared to preimplantation genetic diagnosis","volume":"20","author":"von Hammerstein","year":"2019","journal-title":"BMC Med Ethics."},{"key":"B58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40291-020-00445-y","article-title":"The future of in utero gene therapy","volume":"24","author":"Peranteau","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-med-112717-094629","article-title":"Ethics of human genome editing","volume":"70","author":"Coller","year":"2019","journal-title":"Ann Rev Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/jcmm.14916","article-title":"CRISPR\/Cas9-mediated genome editing: from basic research to translational medicine","volume":"24","author":"Jacinto","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/ijms19092721","article-title":"In vivo genome editing as a therapeutic approach","volume":"19","author":"Ho","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","article-title":"Non-viral delivery to enable genome editing","volume":"37","author":"Rui","year":"2019","journal-title":"Trends Biotechnol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1042\/EBC20170053","article-title":"The genetic basis of disease","volume":"62","author":"Jackson","year":"2018","journal-title":"Essays Biochem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000329420","article-title":"Fragile X syndrome: the GABAergic system and circuit dysfunction","volume":"33","author":"Paluszkiewicz","year":"2011","journal-title":"Dev Neurosci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","article-title":"Correction of fragile X syndrome in mice","volume":"56","author":"D\u00f6len","year":"2007","journal-title":"Neuron"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/mp.2015.113","article-title":"Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders","volume":"20","author":"Barnes","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","article-title":"Fragile X targeted pharmacotherapy: lessons learned and future directions","volume":"9","author":"Erickson","year":"2017","journal-title":"J Neurodev Disord"},{"key":"B68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-019-1506-7","article-title":"Down syndrome: current status, challenges and future perspectives","volume":"5","author":"Kazemi","year":"2016","journal-title":"Int J Mol Cell Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tins.2011.11.001","article-title":"Trisomy 21 and early brain development","volume":"35","author":"Haydar","year":"2012","journal-title":"Trends Neurosci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/cells9010239","article-title":"Applications of genome editing technology in research on chromosome aneuploidy disorders","volume":"9","author":"Akutsu","year":"2020","journal-title":"Cells"},{"key":"B71","doi-asserted-by":"publisher","first-page":"371","DOI":"10.18502\/ijph.v48i3.878","article-title":"Combination of genetics and nanotechnology for down syndrome modification: a potential hypothesis and review of the literature","volume":"48","author":"Tafazoli","year":"2019","journal-title":"Iran J Public Health"},{"key":"B72","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.devcel.2019.12.015","article-title":"Silencing trisomy 21 with XIST in neural stem cells promotes neuronal differentiation","volume":"52","author":"Czermi\u0144ski","year":"2020","journal-title":"Dev Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/jbiol95","article-title":"X-chromosome inactivation: the molecular basis of silencing","volume":"7","author":"Panning","year":"2008","journal-title":"J Biol"},{"key":"B74","first-page":"55","article-title":"GM2-gangliosidosis (Sandhoff and Tay Sachs disease): diagnosis and neuroimaging findings (An Iranian pediatric case series)","volume":"8","author":"Karimzadeh","year":"2014","journal-title":"Iran J Child Neurol"},{"key":"B75","first-page":"716","article-title":"The molecular basis of HEXA mRNA deficiency caused by the most common Tay-Sachs disease mutation","volume":"56","author":"Boles","year":"1995","journal-title":"Am J Hum Genet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa073679","article-title":"Long-term effects of caffeine therapy for apnea of prematurity","volume":"357","author":"Schmidt","year":"2007","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0170545","DOI":"10.1371\/journal.pone.0170545","article-title":"Single Dose Caffeine Protects the Neonatal Mouse Brain against Hypoxia Ischemia","volume":"12","author":"Winerdal","year":"2017","journal-title":"PLoS ONE."},{"key":"B78","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ped.12079","article-title":"Comparative effects of respiratory stimulants on hypoxic neuronal cell injury in SH-SY5Y cells and in hippocampal slice cultures from rat pups","volume":"55","author":"Tanaka","year":"2013","journal-title":"Pediatr Int"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1007\/s12035-020-01867-9","article-title":"Defining a time window for neuroprotection and glia modulation by caffeine after neonatal hypoxia-ischaemia","volume":"57","author":"Di Martino","year":"2020","journal-title":"Mol Neurobiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000509365","article-title":"Caffeine restores background EEG activity independent of infarct reduction after neonatal hypoxic ischemic brain injury","volume":"42","author":"Sun","year":"2020","journal-title":"Dev Neurosci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"11458","DOI":"10.1038\/s41598-017-11574-6","article-title":"Acute doses of caffeine shift nervous system cell expression profiles toward promotion of neuronal projection growth","volume":"7","author":"Yu","year":"2017","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.epag.2018.09.001","article-title":"Association between adenosine receptor gene polymorphism and response to caffeine citrate treatment in apnea of prematurity; An Egyptian single-center study","volume":"66","author":"Mokhtar","year":"2018","journal-title":"Egypt Pediatr Assoc Gazette"},{"key":"B83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/children6110118","article-title":"Caffeine and clinical outcomes in premature neonates","volume":"6","author":"Kumar","year":"2019","journal-title":"Children (Basel, Switzerland)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nbt.3803","article-title":"Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions","volume":"35","author":"Kim","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41467-020-14465-z","article-title":"Expanding the genome-targeting scope and the site selectivity of high-precision base editors","volume":"11","author":"Tan","year":"2020","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s42003-019-0745-3","article-title":"Cytosine base editor 4 but not adenine base editor generates off-target mutations in mouse embryos","volume":"3","author":"Lee","year":"2020","journal-title":"Commun Biol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.aaw7166","article-title":"Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice","volume":"364","author":"Jin","year":"2019","journal-title":"Science (New York, NY)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.aav9023","article-title":"Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq","volume":"364","author":"Wienert","year":"2019","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.neuro.2011.12.009","article-title":"Barriers in the developing brain and Neurotoxicology","volume":"33","author":"Ek","year":"2012","journal-title":"Neurotoxicology."},{"key":"B90","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"B92","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","article-title":"Selection of an efficient AAV vector for robust CNS transgene expression","volume":"15","author":"Hanlon","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B93","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.omtn.2019.04.015","article-title":"Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa","volume":"16","author":"Lau","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B94","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat Neurosci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","article-title":"The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier","volume":"27","author":"Hordeaux","year":"2019","journal-title":"Mol Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS ONE."},{"key":"B98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/hum.2019.186","article-title":"Ly6a differential expression in blood-brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B","volume":"31","author":"Batista","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1038\/s41598-019-40222-4","article-title":"Magnetically guided non-invasive CRISPR-Cas9\/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection","volume":"9","author":"Kaushik","year":"2019","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2006.10.006","article-title":"Neurologic and neurodevelopmental manifestations of pediatric HIV\/AIDS: a global perspective","volume":"11","author":"Van Rie","year":"2007","journal-title":"EJPN"},{"key":"B101","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/B978-0-444-63849-6.00008-6","article-title":"NeuroAIDS in children","volume":"152","author":"Wilmshurst","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1261\/rna.067355.118","article-title":"Staphylococcus aureus Cas9 is a multiple-turnover enzyme","volume":"25","author":"Yourik","year":"2019","journal-title":"RNA (New York, NY)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nbt.3055","article-title":"In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9","volume":"33","author":"Swiech","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest"},{"key":"B107","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1021\/acsnano.7b04495","article-title":"In vivo neuroimaging of exosomes using gold nanoparticles","volume":"11","author":"Betzer","year":"2017","journal-title":"ACS Nano"},{"key":"B108","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12195-016-0458-3","article-title":"Elucidation of exosome migration across the blood-brain barrier model in vitro","volume":"9","author":"Chen","year":"2016","journal-title":"Cell Mol Bioeng"},{"key":"B109","doi-asserted-by":"publisher","first-page":"8278","DOI":"10.1038\/s41598-019-44569-6","article-title":"Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood-brain barrier penetration","volume":"9","author":"Khongkow","year":"2019","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"B112","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/AOG.0000000000003327","article-title":"Genetically modified babies and a first application of clustered regularly interspaced short palindromic repeats (CRISPR-Cas9)","volume":"134","author":"Rose","year":"2019","journal-title":"Obstet Gynecol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat Med"},{"key":"B115","first-page":"127","article-title":"Clinical images: postterm newborn with lissencephaly presented with seizure: case report and review of literature","volume":"15","author":"Alhasan","year":"2015","journal-title":"Ochsner J"},{"key":"B116","first-page":"667","article-title":"CRISPR, Patents, and the public health","volume":"90","author":"Sherkow","year":"2017","journal-title":"Yale J Biol Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1089\/crispr.2019.0052","article-title":"The daunting economics of therapeutic genome editing","volume":"2","author":"Wilson","year":"2019","journal-title":"CRISPR J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/d41586-019-00814-6","article-title":"NIH supports call for moratorium on clinical uses of germline gene editing","volume":"567","author":"Wolinetz","year":"2019","journal-title":"Nature"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.592571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T16:57:32Z","timestamp":1615827452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.592571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":118,"alternative-id":["10.3389\/fped.2021.592571"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.592571","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"article-number":"592571"}}